FGF-4 Antibody [Biotin]

• Reactivity: Hu
• Applications: WB, IHC, ELISA(Det)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

FGF-4 Antibody [Biotin] Summary

• Immunogen: E. coli-derived recombinant human FGF-4
  Ala31-Leu206
  Accession # P08620
• Specificity: Detects human FGF-4 in ELISAs and Western blots. In sandwich ELISAs, less than 0.3% cross-reactivity with recombinant human (rh) FGF‑6 is observed, and less than 0.2% cross-reactivity with rhFGF acidic, rhFGF basic, rhFGF-5, -7, -9, -10, -17, and -19 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FGF4
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Immunohistochemistry 5-15 ug/mL
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture: Human FGF-4 Antibody (Catalog # MAB635)
  ELISA Detection: Human FGF-4 Biotinylated Antibody (Catalog # BAF235)
  Standard: Recombinant Human FGF-4 (Catalog # 235-F4)
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGF-4 Antibody [Biotin]

• FGF4
• FGF-4
• fibroblast growth factor 4
• HBGF-4
• HBGF-4Transforming protein KS3
• heparin secretory transforming protein 1
• Heparin secretory-transforming protein 1
• Heparin-binding growth factor 4
• HST-1
• HST-1HSTF-1
• HSTF1fibroblast growth factor 4 splice isoform
• HSTFGF-4
• human stomach cancer, transforming factor from FGF-related oncogene
• kaposi sarcoma oncogene
• KFGF
• K-FGF
• KS3
• oncogene HST

Background

FGF-4, the product of a developmentally regulated gene (hst-1), is a member of the FGF family that is efficiently secreted. The gene for FGF-4 (also known as FGFK or K-FGF for Kaposi sarcoma-associated FGF) was initially discovered as a transforming gene by the NIH-3T3 focus formation assay using DNA derived from human tumors (including stomach and colon cancers, hepatocellular carcinomas, and Kaposi’s sarcomas). FGF-4 does not seem to be expressed in normal adult tissues. However, expression of the gene is spatially and temporally regulated during embryonic development. The murine homologue of human FGF-4 has been cloned and shown to be 82% homologous to the human protein at the amino acid sequence level. Human FGF-4 has been shown to exhibit cross species activity.

In vitro, FGF-4 is mitogenic for fibroblasts and endothelial cells. FGF-4 has been shown to be a potent angiogenesis promoter in vivo. FGF-4 has potent transforming potential apparently through an autocrine mechanism of action. FGF-4 plays a key role in limb development and has been identified as the molecular mediator of the activities of the apical ectodermal ridge that is required for directing the outgrowth and patterning of vertebrate limbs.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FGF4
• Uniprot:
  • P08620()